Transcript Slide 1

RESEARCH
PRIVACY AND HIPAA
With
S. Joseph Austin, JD, LL.M, Regulatory Coordinator
Jan Hewett, JD, BSN, Director, IRBMED
Robin Sedman, MAEd, MSN, Senior Associate Regulatory Analyst
Lauren Shellenberger, JD, RN, Director, Compliance Policy & Education
Alan Sugar, MD, Co-Chair, IRBMED
Moderated by: Jennifer Galland, MHA, Board Member, IRBMED
October 18, 2011
2:00 to 4:00
CVC Danto Auditorium
I.
II.
III.
IV.
V.
VI.
VII.
VIII.
IX.
X.
IRBMED
Privacy Board
HIPAA
Protected Health Information
Authorization
Waiver of HIPAA Authorization
Certification Preparatory to Research
Decedents
De-Identified Data Sets
Limited Data Sets
Institutional Review Boards
of the University of
Michigan Medical School
(IRBMED)
http://www.med.umich.edu/irbmed/
IRBMED:
Structure
Director
Jan Hewett
Office Manager
Lisa Kiel
Support Staff
Maria Camilleri
Colleen Bouton
Patti Meredith
Review Teams
A1
A2
B1
B2
C1
Coordinators
Pat Gordon, eResearch
Georgia Marvin, Compliance
Education
Joseph Austin, Senior Education & Regulatory
Brian Seabolt, Technical Writer
Monica Stiddom, Education
Expedited Reviewer
Jennifer Galland
IRBMED:
Structure
A1
A2
B1
B2
C1
Gwendolyn Young
Ann Dillon
Cheryl Jamnick
Robin Sedman
Carol Hutsko
Zan Daley
Rosalind Fantone
Lark Speyer
Nora Coury
Derrick Mann
Cecilia Brenner
Aaron Rankin
Faith Penix
Kara Rumsey
Wendy Ulmer
Geriatrics
Kinesiology
Neurology
Neurosurgery
Obstetrics & Gynecology
Ophthalmology
Otolaryngology
Pathology
Physical Medicine and
Rehabilitation
Surgery (General,
Orthopedic, Head &
Neck, Pediatric, Plastic,
Vascular)
Allergy (AP)
Anesthesiology / Pain
(AP)
Dentistry / Surgical (AP)
Dermatology (AP)
Emergency Medicine
Gastroenterology (AP)
Hepatic / Pancreative
(AP)
Hematology (excl
cooperative studies)
Infectious Disease (AP)
HIV/AIDS
Nursing
Pharmacy
Urology (Surg & Onc)
Radiology Oncology
Cardiac Electrophys (AP)
Cardiology (AP)
Cardio-Thoracic Surgery
(AP)
Endocrin / Metabolism
(AP)
Genetics/Microbiology
Hypertension (AP)
Nephrology (AP)
Pulmonology (AP)
Rheumatology
Transplant (AP) (Heart,
Lung, Kidney, Liver)
Behavioral Medicine
(AP)
Complementary
Medicine (CAM)
Family Medicine
Graduate Medical
Education
Internal Medicine (see
also B1/C1)
Pediatrics
Psychology Genetics /
Neuro-Psych (AP)
Public Health
Radiology
Radiology Devices
Social Work / Social
Sciences
Oncology / Cancer (AP)
Bone Marrow
Transplant
Pediatric
Surgical
Departments (exclude
Urology)
Hem/Onc
Medical Oncology
CTO Studies
Privacy Board
PRIVACY BOARD:
Responsibility

Privacy Board oversees research aspects of HIPAA

Compliance Office oversees clinical aspects of
HIPAA.
PRIVACY BOARD:
Members
Chair:
Alan Sugar, MD
Members:
Fran Lyman, MLS
Duke Morrow, DMin
Michael Paschke, MA
Joy Stair, MS, RN
Coordinator: S Joseph Austin, JD, LL.M
HIPAA
HIPAA:
Basics

HIPAA is the Health Insurance Portability and
Accountability Act.

Purpose:
Protect the privacy of individuals’ personal health
information.
 Provide physical and electronic security for PHI.
 Simplify billing.
 Provide rights for patients regarding access to and use of
their medical information.

HIPAA:
Authorizations

A HIPAA Authorization is signed permission from an individual that
allows that individual’s PHI to be used or disclosed for reasons
other than Treatment, Payment or Healthcare Operations (TPO
purposes).

The Authorization must include:





A description of the PHI to be used/disclosed.
Who will make the disclosure.
To whom the disclosure will be made.
An expiration date.
The purpose of the disclosure.
Note: An individual may revoke a signed authorization at any time.
Protected Health
Information (PHI)
PROTECTED HEALTH INFORMATION:
Defined

Protected Health Information (PHI) is any
information in the medical record or designated
record set that can be used to identify an
individual and that was created, used, or disclosed
in the course of providing a health care service
such as treatment, payment, or operations.
Note: PHI may be in any form or media, including electronic,
paper, or oral.
PROTECTED HEALTH INFORMATION:
HIPAA

HIPAA regulations allow researchers to access and use PHI when
necessary to conduct research.

However, HIPAA only affects research that uses, creates, or discloses PHI
that will be entered in to the medical record or will be used for healthcare
services, such as treatment, payment, or operations.

Examples:


PHI is used in research studies when researchers will access existing medical
records for research information.
Studies that create new medical information because a health care service is
being performed as part of research, such as diagnosing a health condition or
using a new drug or device for treating a health condition.
PROTECTED HEALTH INFORMATION:
Individually Identifiable Health Information
Individually identifiable health information is information (including demographic
information) that is related to:
At least one of the following three:



The past, present, or future physical or mental health or condition of the individual.
The health care provided to the individual.
The past, present, or future payment for health care provided to the individual,
AND

Either identifies the individual or there is a reasonable basis to believe that the
information could be used to identify the individual.
PROTECTED HEALTH INFORMATION:
Identifiers
PHI includes the following:










Names
Geographic subdivisions smaller
than a state.
Dates directly related to the
individual except year
All ages over 89 and/or dates
indicating an age over 89
Telephone numbers
Fax numbers
Email addresses
Social security numbers
Medical record numbers
Health plan numbers









Account numbers
Certificate or license numbers
Vehicle identification/serial
numbers, including license plate
numbers
Device identification/serial numbers
Universal Resource Locators (URLs)
Internet protocol (IP) addresses
Biometric identifiers, including
finger and voice prints
Full face photographs and
comparable images
Any unique identifying number,
code, or other similar information.
PROTECTED HEALTH INFORMATION:
Use v Disclosure

“Use” refers to the access, sharing,
and utilization of PHI within the
Covered Entity.

“Disclosure” refers to the sharing of
PHI to individuals and entities
outside of the Covered Entity
PROTECTED HEALTH INFORMATION:
Covered v Not Covered

PHI does not, however, cover employment records
that a covered entity maintains in its capacity as an
employer.

PHI may also not include education and certain
other records subject to the Family Educational
Rights and Privacy Act, 20 U.S.C. §1232g.
PROTECTED HEALTH INFORMATION:
Re-Identification

Additional standards exist to protect an individual's privacy
from re-identification.




Any code used to replace the identifiers in datasets cannot be
derived from information related to the individual.
For example, a subject's initials cannot be used to code their
data because the initials are derived from their name.
Also, the method used to derive the codes may not be disclosed.
Additionally, the researcher must not have actual
knowledge that the research subject could be re-identified
from the remaining identifiers.
Waiver of HIPAA
Authorization
WAIVER OF HIPAA AUTHORIZATION:
Types of Applications
There are three types of applications that require
a Waiver of Authorization:

Regulated Studies, when simultaneously
requesting:
A
Waiver of Informed Consent
OR
 A Waiver of Documentation of Informed Consent
WAIVER OF HIPAA AUTHORIZATION:
Types of Applications

Exempt Studies, when accessing PHI

Non-Regulated Studies, when accessing PHI
Note: Requests for a Waiver for Regulated studies may
be granted by the Full Board or by expedited review.
Waivers for Exempt or Non-Regulated studies may be
granted by the Full Board, expedited review, or by
Privacy Board.
WAIVER OF INFORMED CONSENT:
Criteria
Waivers should only be granted for studies where the study
team will access PHI if the following are met:




There is no more than minimal risk to the privacy of the
individuals.
The research could not practicably be conducted without
the waiver of consent or waiver of documentation of
consent.
The research could not practicably be conducted without
the requested use or disclosure of PHI.
Whenever appropriate, the subjects will be provided with
additional pertinent information after participation.
HIPAA:
Authorizations

A HIPAA Authorization is signed permission from an individual that
allows that individual’s PHI to be used or disclosed for reasons
other than Treatment, Payment or Healthcare Operations (TPO
purposes).

The Authorization must include:





A description of the PHI to be used/disclosed.
Who will make the disclosure.
To whom the disclosure will be made.
An expiration date.
The purpose of the disclosure.
Note: An individual may revoke a signed authorization at any time.
WAIVER OF HIPAA AUTHORIZATION:
Criteria








There is an adequate plan in place to protect patient identifiers and PHI from improper use
and disclosure.
There is an adequate plan to destroy the identifiers at the earliest opportunity consistent
with the conduct of the research, unless there is a Privacy Review Board-approved health or
research justification for retaining the identifiers or such retention is otherwise required by
law.
There are adequate written assurances that the PHI will not be reused or disclosed to any
other person or entity, except as required by law, for authorized oversight of the research
study, or for other research for which the use or disclosure would be permitted by HIPAA.
The Waiver or Alteration of Authorization will not adversely affect the rights and welfare of
the subjects
The research could not practicably be conducted without the Waiver or Alteration of
Authorization.
The research could not practicably be conducted without access to and use of the PHI.
Whenever appropriate, the subjects (including their physicians, as applicable) are provided
with additional pertinent information after participation.
Where the Principal Investigator anticipates the disclosure of PHI outside the Covered Entity
(as that may be determined from time to time), the Principal Investigator must account for
each disclosure and retain records of such disclosures.
WAIVER OF HIPAA AUTHORIZATION:
eResearch Application

The study team will need to complete Sections 25-1
and 25-2 for a Waiver of HIPAA Authorization


Note: eResearch logic does not always force these sections;
they are, however, necessary
The study team will need to complete Section 25.1 and
the following when applicable:
Section 25-3 when “Preparatory to Research”
 Section 25-4 when “Limited Data Set”
 Section 25-5 when “Deidentified Data Set”
 Section 25-6 when “Decedents”

Certification
Preparatory to
Research
CERTIFICATION PREPARATORY TO
RESEARCH

Projects that are preparatory to research are not
regulated under the Common Rule.

However, when researchers will be accessing
Protected Health Information (PHI) to assess the
feasibility of a research project, the activities are
subject to HIPAA.

To ensure compliance with HIPAA, the project will
need to be reviewed by the Privacy Board.
CERTIFICATION PREPARATORY TO
RESEARCH

In order to use PHI preparatory to research purposes, the
researcher will need to affirm the following:




The use or disclosure of the PHI is solely to prepare to conduct
research.
None of the PHI will be removed from the covered entity.
Access to the PHI is necessary for the research purpose.
Importantly, researchers may not record identifiers and
may not use the accessed information in order to identify
or recruit subjects for the study.
CERTIFICATION PREPARATORY TO
RESEARCH

Researchers should complete a Not-Regulated
application through eResearch.

As part of the submission, the researcher will need to
complete Sections 25-1 and 25-3 of the application.

The completed application will then be reviewed by
the Privacy Board.
Decedents
DECEDENTS:
Basics

Research involving decedents is not regulated
under the Common Rule.

However, when researchers will be accessing
Protected Health Information (PHI) in order to
create a limited data set, the activities are subject
to HIPAA.

To ensure compliance with HIPAA, the project will
need to be reviewed by the Privacy Board.
DECEDENTS:
Criteria

In order use the PHI of decedents for research
purposes, the researcher will need to affirm:
 The
use or disclosure being sought is solely for
research on the PHI of decedents.
 The PHI being sought is necessary for the research.
 At the request of the covered entity, the research will
be able to provide documentation of the death of the
individuals about whom information is being sought.
DECEDENTS:
Process

Researchers should complete a Not-Regulated
application through eResearch.

As part of the submission, the researcher will need
to complete Sections 25-1 and 25-6 of the
application.

The completed application will then be reviewed
by the Privacy Board.
DE-IDENTIFIED
DATA SETS
De-Identified Data Sets:
Definition

A de-Identified data set is a data set that meets
both of the following:
 Does
not identify any individual that is a subject of the
data.
 Does not provide any reasonable basis for identifying
any individual that is a subject of the data.
De-Identified Data Sets:
Methods for De-Identification

There are two methods for deidentifying information:
 The
removal of certain
identifiers
 The statistical method
DE-IDENTIFIED DATA SETS:
Removal of Identifiers
Under the first method, the identifiers that must be removed include the
following:










Names
Geographic subdivisions smaller
than a state.
Dates directly related to the
individual except year
All ages over 89 and/or dates
indicating an age over 89
Telephone numbers
Fax numbers
Email addresses
Social security numbers
Medical record numbers
Health plan numbers









Account numbers
Certificate or license numbers
Vehicle identification/serial
numbers, including license plate
numbers
Device identification/serial numbers
Universal Resource Locators (URLs)
Internet protocol (IP) addresses
Biometric identifiers, including
finger and voice prints
Full face photographs and
comparable images
Any unique identifying number,
code, or other similar information.
DE-IDENTIFIED DATA SETS:
Statistical Method

An individual with knowledge of and experience with generally
accepted statistical and scientific methods for rendering
information not individually identifiable must provide certification
that the data is de-identified.

The individual should find that the risk is very small that the
information could be used (either alone or in combination with
other reasonably available information) to identify any individual
who is a subject of the data.

Additionally, the methods and results of the analysis must be
documented.
DE-IDENTIFIED DATA SETS:
Creating a De-Identified Data Set

Research involving a de-identified data set is not
regulated under the Common Rule.

However, when researchers will be accessing PHI in
order to create a de-identified data set, the activities
are subject to HIPAA.

To ensure compliance with HIPAA, the project will
need to be reviewed by the Privacy Board.
DE-IDENTIFIED DATA SETS:
Using a De-Identified Data Set

Pre-existing, de-identified data sets are not subject
to the requirements of the HIPAA Privacy Rule
since they do not include individually identifiable
information.

However, in order to ensure compliance with
HIPAA, the project should be reviewed by the
Privacy Board.
LIMITED DATA SETS
LIMITED DATA SETS:
Basics

A limited data set is a distinct category
of protected health information (PHI)
where certain identifiers have been
removed.

Importantly, these identifiers must have
been removed for the individuals as well
as their relatives, household members,
and employers (when applicable).
LIMITED DATA SETS:
Removed Identifiers
The identifiers that must be removed include the following:








Names
Postal address information other
than town/city, state, and zip
code
Telephone numbers
Fax numbers
Email addresses
Social Security number
Medical record numbers
Vehicle identification/serial
numbers, including license plate
numbers








Health plan numbers
Account numbers
Certificate or license numbers
Device identification/serial
numbers
Universal Resource Locators
(URLs)
Internet Protocol (IP) addresses
Biometric identifiers, including
finger and voice prints
Full face photographs and
comparable images
LIMITED DATA SETS:
Data Use Agreements

A limited data set may be used and disclosed for
research purposes, as well as for health care
operations and public health purposes.

Before any such use, however, the recipient must enter
into a data use agreement.

The agreement guarantees that certain measures will
be taken to safeguard the PHI.
LIMITED DATA SETS:
Creating a Limited Data Set

Research involving a limited data set is not regulated
under the Common Rule.

However, when researchers will be accessing PHI in
order to create a limited data set, the activities are
subject to HIPAA.

To ensure compliance with HIPAA, the project will
need to be reviewed by the Privacy Board.
LIMITED DATA SETS:
Using a Limited Data Set

Research using a pre-existing limited data set is not
regulated under the Common Rule.

However, in order to ensure compliance with HIPAA,
the project should be reviewed by the Privacy Board.

In order to use a limited data set, the recipient of the
data must first enter into a data use agreement. After
the agreement is finalized, a Not-Regulated application
should be completed through eResearch.